about
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesA current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsRational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium.Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protectionAngiotensin receptor blockers and risk of myocardial infarction: systematic review.Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interactionClinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyIndications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskJBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Emerging drugs for diabetic nephropathy.Therapeutic potential of angiotensin receptor blockers in hypertension.Valsartan in the treatment of heart attack survivorsVascular benefits of angiotensin receptor blockers.Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.Angiotensin receptor blockers in hypertension. New insights from Japan.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer.Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.Angiotensin II receptor antagonists in acute coronary syndromes.Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLCThe Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarctionCombined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke.Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension.Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves.Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.Angiotensin receptor blockers and endpoint protection.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document2007 ESH‐ESC Guidelines for the management of arterial hypertension
P2860
Q24658205-DB9A829C-D3F9-4D25-8C00-10767FE58CACQ26767278-D1859F0B-B033-4E4A-A016-B0B0C4A33C9BQ30432209-19D7DCA7-8247-40B2-AC9C-77879929E7BCQ33245267-0AAC4416-D5E4-4404-AE94-576FFC735A39Q33403831-35709B56-BC91-44C1-BA34-A83454C7A805Q33674848-C274FA28-3ACB-4577-9A3C-7E74A83A8173Q34068728-4B5E6FF6-F36E-4D8A-9219-A991B68A39A6Q34081519-F8F573BE-809F-421D-ABC8-E762FD2697EEQ34231611-885196C9-C752-47B7-AF4E-0D5A5E0DEE23Q34386587-3F631DA7-7A4F-428B-9749-7EA9997189AAQ35539305-90CA4ED7-0E20-4AEB-A112-7FAE26F28ABBQ35808362-89103BEE-FEAD-4D15-BEFA-19956BB8D73BQ36249947-47F7BEF4-B2B3-467D-9109-F0CE6E7A3F47Q36302833-0B54EF50-F691-460D-BC52-C3BD463856C9Q36302838-9827DA42-2661-4B6E-B8D6-8FB1C6B8093CQ36491825-5C036B56-E7E7-4C93-9703-B1C32972ABDCQ36744015-CBAA7D3E-DEC5-46EC-8A05-917F477F53FCQ36861584-B242F25E-9987-4609-B5D7-A8ADC4E0CAC2Q37642900-E7E7CFCD-F2A4-4D80-A3F4-1B8ADC6F3376Q37691240-100E5EED-FA2B-4537-8C62-AC0E287196F1Q37827882-47C10790-ED64-42AE-9B9D-5E1C31048777Q37869264-21DDDA90-C53E-447C-9B5A-98EA0E34F96CQ37879662-F4CCF968-35FC-43C1-9A1B-65DBFAA73F13Q38001305-3E5DA4C0-72C8-441B-9270-DC67FE54DEB6Q38167346-0FF76F3E-91F4-4AEA-8D03-52B1B032D6FBQ39643542-B4A9DD05-217B-4344-8E16-DA2A643073EAQ41469746-12D7B424-5725-448A-BF42-AC228444078FQ42123922-03D98831-878C-416C-BFCA-C6F7037A9BD6Q42758342-A5878977-C09C-48E7-9F7A-1083E084DDE5Q43060073-7754F41B-7B01-4FB4-B311-BBA05017BA38Q43060094-19561406-7A84-4858-A9FE-6B31EAF88701Q43060486-708ED07A-3AB3-4F78-A5BA-099F147CE466Q43060502-927CD33C-D2A2-4B97-8210-CF9105E949CCQ43811034-E4817FC4-191B-4C24-A4C7-B5F5CA0C0BECQ46668164-0D8C5A87-1859-4A19-A4CE-E00F5CBAB448Q46886153-611D4D90-0C28-40D6-A78B-0F17032BCC3CQ51800530-2E5017DE-FBC3-4D29-912F-CE1961864D6BQ53845954-7CD6E919-A797-4EB0-95C3-710BB0C159AEQ56970710-4F6846D3-26AC-4C8C-89D2-1410F6EBA37CQ56970799-93152CEC-5AA6-47E6-BA4E-CE93414FC831
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Angiotensin receptor blockers and myocardial infarction
@ast
Angiotensin receptor blockers and myocardial infarction
@en
Angiotensin receptor blockers and myocardial infarction
@nl
type
label
Angiotensin receptor blockers and myocardial infarction
@ast
Angiotensin receptor blockers and myocardial infarction
@en
Angiotensin receptor blockers and myocardial infarction
@nl
prefLabel
Angiotensin receptor blockers and myocardial infarction
@ast
Angiotensin receptor blockers and myocardial infarction
@en
Angiotensin receptor blockers and myocardial infarction
@nl
P2860
P1433
P1476
Angiotensin receptor blockers and myocardial infarction
@en
P2093
Marty Strauss
Subodh Verma
P2860
P304
P356
10.1136/BMJ.329.7477.1248
P407
P577
2004-11-27T00:00:00Z